What they were paid
Definium Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $58,000 | $0 | $399,827 | $0 | $457,827 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Definium Therapeutics, Inc. DEF 14A filed April 27, 2026, accession 0001193125-26-182034, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Definium Therapeutics pays directors a $40,000 cash retainer and $450,000 in Options/RSUs/PSUs.
Committees
FY2025 · as the proxy prints themCompensation (Chair) · Nominating/Governance
The rest of the Definium Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Andreas Krebs | Independent Director | $484,827 |
| Carol A. Vallone | Chair of the Board | $496,827 |
| David Gryska | Independent Director | $458,827 |
| Dr. Roger Crystal | Independent Director | $456,827 |
| Robert Barrow | Director | $0 |
| Roger Adsett | Independent Director | — |
The full Definium Therapeutics compensation record
free company briefThis page is one director within Definium Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat